Baxter establishes $200M VC fund
This article was originally published in Clinica
Baxter International has become the latest healthcare multinational to establish its own venture capital fund. The company has announced plans to create Baxter Ventures to invest up to $200m in promising early-stage companies developing therapies that complement Baxter's existing portfolio. With many traditional venture capital houses moving away from early-stage drug discovery and development investing, an increasing number of pharmaceutical companies are creating their own corporate venture arms to fill the innovation investment vacuum.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.